Regeneron Pharmaceuticals Inc (REGN) : Simplex Trading reduced its stake in Regeneron Pharmaceuticals Inc by 20.21% during the most recent quarter end. The investment management company now holds a total of 3,881 shares of Regeneron Pharmaceuticals Inc which is valued at $1,513,823 after selling 983 shares in Regeneron Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on Oct 7, 2016.Regeneron Pharmaceuticals Inc makes up approximately 0.20% of Simplex Trading’s portfolio.
Other Hedge Funds, Including , Exxonmobil Investment Management Inc Tx reduced its stake in REGN by selling 920 shares or 4.56% in the most recent quarter. The Hedge Fund company now holds 19,270 shares of REGN which is valued at $7,516,456. Regeneron Pharmaceuticals Inc makes up approx 0.16% of Exxonmobil Investment Management Inc Tx’s portfolio.Chevy Chase Trust Holdings reduced its stake in REGN by selling 3,626 shares or 4.98% in the most recent quarter. The Hedge Fund company now holds 69,225 shares of REGN which is valued at $27,177,735. Regeneron Pharmaceuticals Inc makes up approx 0.15% of Chevy Chase Trust Holdings’s portfolio. Independent Portfolio Consultants added REGN to its portfolio by purchasing 60 company shares during the most recent quarter which is valued at $23,556. Regeneron Pharmaceuticals Inc makes up approx 0.01% of Independent Portfolio Consultants’s portfolio.Bnp Paribas Arbitrage Sa boosted its stake in REGN in the latest quarter, The investment management firm added 27,576 additional shares and now holds a total of 68,668 shares of Regeneron Pharmaceuticals Inc which is valued at $26,959,057. Regeneron Pharmaceuticals Inc makes up approx 0.11% of Bnp Paribas Arbitrage Sa’s portfolio.Eqis Capital Management reduced its stake in REGN by selling 97 shares or 2.13% in the most recent quarter. The Hedge Fund company now holds 4,458 shares of REGN which is valued at $1,750,211. Regeneron Pharmaceuticals Inc makes up approx 0.11% of Eqis Capital Management’s portfolio.
Regeneron Pharmaceuticals Inc opened for trading at $390.33 and hit $390.98 on the upside on Friday, eventually ending the session at $390.06, with a gain of 0.38% or 1.46 points. The heightened volatility saw the trading volume jump to 5,17,011 shares. Company has a market cap of $41,071 M.
On the company’s financial health, Regeneron Pharmaceuticals Inc reported $2.82 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.65. The company had revenue of $1213.00 million for the quarter, compared to analysts expectations of $1237.52 million. The company’s revenue was up 21.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.89 EPS.
Many Wall Street Analysts have commented on Regeneron Pharmaceuticals Inc. Shares were Downgraded by Robert W. Baird on Aug 5, 2016 to ” Neutral” and Lowered the Price Target to $ 448 from a previous price target of $505 .
Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.